zintick

Supernus Pharmaceuticals SUPN

Supernus Pharmaceuticals, Inc. · Nasdaq · Pharmaceutical Preparations

$28.15-32.85%close on Nov. 3, 2026 · volume 7.8M · Yahoo Finance

Price, last 51 sessions

$30.00$35.00$40.00$45.00Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 3, 2026 · high $45.36 · low $28.15 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

No open-market insider buying or selling in the Form 4s filed since July 24, 2026.

Recent SEC filings

All 37 →
  • 4Nov. 2, 2026, 4:14 p.m. ETView on SEC.gov
  • 4Nov. 2, 2026, 4:18 p.m. ETView on SEC.gov
  • 4Nov. 2, 2026, 4:15 p.m. ETView on SEC.gov
  • 4Nov. 2, 2026, 4:11 p.m. ETView on SEC.gov
  • 4Nov. 2, 2026, 4:20 p.m. ETView on SEC.gov
  • 4Nov. 2, 2026, 4:17 p.m. ETView on SEC.gov
  • 8-KNov. 2, 2026, 10:50 a.m. ETView on SEC.gov

    Delisting notice / failure to meet listing standard

    AI summary, unreviewedSupernus Pharmaceuticals, Inc. Stock to Be Delisted From Nasdaq Following Completion of Merger on November 2, 2026

  • 8-KNov. 2, 2026, 9:28 a.m. ETView on SEC.gov

    Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Creation of a direct financial obligation · Material modification of security holders' rights · Change in control · Amendments to articles or bylaws; fiscal year change · Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedSupernus completes reverse merger with Indivior, issuing 1.5401 Indivior shares per Supernus share and funding a $1.0 billion Indivior special dividend with a $650 million Citibank term loan